Trials
1 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pruritus, Primary Biliary Cholangitis
- Main trialPhase 2
- “A phase 2a, multicenter, randomized, double-blind, placebo-controlled study of TH104 in primary biliary cholangitis (PBC) participants with moderate to severe pruritus.”In the company’s words, NCT06733519 on ClinicalTrials.gov
- Other names
- Nalmefene
Other drugs for Pruritus
- SD-101TriSalus Life Sciences, Inc. · Phase 3
- DupilumabRegeneron · Sanofi · Phase 3
- FexofenadineSanofi · Phase 3
- LinerixibatGSK · Phase 3
- DeucravacitinibBristol Myers Squibb · Phase 3
- RitlecitinibPfizer · Phase 2
Coming up1
- 1 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 1 Mar 2027 | TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis | |
| Phase 4Ended | not given | (ROAR) Reversal of opioid-induced respiratory depression with opioid antagonists - a pharmacokinetic pharmacodynamic modeling study in opioid naïve individuals and chronic opioid users under real-life conditions |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026